Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
- F. Brasó-Maristany, S. Filosto, +25 authors A. Tutt
- Biology, Medicine
- Nature Medicine
- 24 October 2016
Triple-negative breast cancers (TNBCs) have poor prognosis and lack targeted therapies. Here we identified increased copy number and expression of the PIM1 proto-oncogene in genomic data sets of… Expand
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
- A. Gris-Oliver, M. Palafox, +28 authors V. Serra
- Medicine
- Clinical Cancer Research
- 27 March 2020
Purpose: AZD5363/capivasertib is a pan-AKT catalytic inhibitor with promising activity in combination with paclitaxel in triple-negative metastatic breast cancer harboring PI3K/AKT-pathway… Expand
Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer
- Nirmesh Patel, D. Weekes, +18 authors A. Tutt
- Biology, Medicine
- Nature Communications
- 13 March 2018
Triple negative breast cancers (TNBCs) lack recurrent targetable driver mutations but demonstrate frequent copy number aberrations (CNAs). Here, we describe an integrative genomic and RNAi-based… Expand
PIM 1 kinase regulates cell death , tumor growth and chemotherapy response in triple-negative breast cancer
- F. Brasó-Maristany, S. Filosto, +28 authors A. Tutt
- 2017
Triple-negative breast cancers (TNBCs) have poor prognosis and lack targeted therapies. Here we identified increased copy number and expression of the PIM1 proto-oncogene in genomic data sets of… Expand
- 4
- PDF
Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
- F. Brasó-Maristany, S. Filosto, +25 authors A. Tutt
- Medicine
- Nature Medicine
- 2017
Constanze Schneider, Thomas Oellerich, Hanna-Mari Baldauf, Sarah-Marie Schwarz, Dominique Thomas, Robert Flick, Hanibal Bohnenberger, Lars Kaderali, Lena Stegmann, Anjali Cremer, Margarethe Martin,… Expand
1481P Expression of ERBB2 and PD1 mRNA in advanced gastric cancer
- D. Pesántez, F. Brasó-Maristany, +17 authors T. Saurí
- Medicine
- 1 September 2020
23P Clinical, pathological and gene expression features of HER2-low breast cancer
- F. Schettini, N. Chic, +17 authors A. Prat
- Medicine
- 1 May 2020
Abstract 178: PIM1, a novel target in chemotherapy-resistant triple-negative breast cancer
- F. Brasó-Maristany, Simone Filosto, +16 authors A. Tutt
- Biology
- 15 July 2016
Triple-Negative Breast Cancers (TNBCs) are aggressive, associated with poor prognosis and lack targeted therapies, mainly due to the absence of suitable molecular targets. The genomic region 6p21-p25… Expand
ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC).
- G. Griguolo, F. Brasó-Maristany, +7 authors A. Prat
- Medicine
- Annals of oncology : official journal of the…
- 1 May 2019
UK Breast Cancer Research Symposium 2016: Submitted Abstracts
- Sarah L. Maguire, E. Morrison, +38 authors A. Tutt
- Medicine
- Breast Cancer Research and Treatment
- 2016
UK Breast Cancer Research Symposium 2016: Submitted Abstracts The Author(s) 2016. This article is published with open access at Springerlink.com Breast cancer risk alleles in separate gene regulatory… Expand